Quick Answer
AEON Biopharma, Inc. reported R&D Expense of $4.09 million for fiscal year 2025.
AEON Biopharma, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $4.09M | -71.1% |
| 2024 | $14.18M | -59.2% |
| 2022 | $34.75M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $597.0K | -38.6% | -43.9% |
| June 30, 2025 | $1.06M | -76.0% | +29.0% |
| March 31, 2025 | $825.0K | -85.6% | -15.1% |
| September 30, 2024 | $972.0K | -84.8% | -78.1% |
| June 30, 2024 | $4.44M | -50.8% | -22.6% |
| March 31, 2024 | $5.73M | -37.7% | -10.3% |
| September 30, 2023 | $6.39M | -14.6% | +306.1% |
| July 31, 2023 | $1.57M | — | -82.6% |
- AEON Biopharma, Inc. showed a decrease of -71.1% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, AEON Biopharma, Inc.’s r&d expense has declined by 88.2% (from $34.75 million to $4.09 million).
- The most recent figure is from AEON Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: